Zykadia
Zykadia ingredients
| Active ingredient | Strength |
|---|---|
| Ceritinib | 150 mg/1 |
What Zykadia is used for
The FDA lists the approved uses on the official label (below). In the EU, ceritinib is approved as Zykadia for:
Zykadia is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously treated with crizotinib.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Zykadia
- Generic name
- Ceritinib
- Made by
- Novartis Pharmaceuticals Corporation
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA211225
- On the US market since
- 2019
Official information
- MedlinePlus drug information (search for Ceritinib)
In India
- Ceritinib: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zykadia?
Zykadia (Ceritinib) is a cancer medicine made by Novartis Pharmaceuticals Corporation, approved by the US FDA.
What are the ingredients of Zykadia?
Zykadia contains Ceritinib (150 mg/1).
Is Zykadia approved in Europe?
The same active substance is approved in the EU as Zykadia.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA